AMNEAL PHARMACEUTICALS INC (AMRX) Fundamental Analysis & Valuation

NASDAQ:AMRX • US03168L1052

Current stock price

12.65 USD
-0.17 (-1.33%)
At close:
12.9 USD
+0.25 (+1.98%)
Pre-Market:

This AMRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. AMRX Profitability Analysis

1.1 Basic Checks

  • In the past year AMRX was profitable.
  • In the past year AMRX had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: AMRX reported negative net income in multiple years.
  • AMRX had a positive operating cash flow in each of the past 5 years.
AMRX Yearly Net Income VS EBIT VS OCF VS FCFAMRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M -400M

1.2 Ratios

  • The Return On Assets of AMRX (1.96%) is better than 82.20% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 11.24%, AMRX belongs to the top of the industry, outperforming 90.58% of the companies in the same industry.
  • AMRX had an Average Return On Invested Capital over the past 3 years of 10.04%. This is below the industry average of 13.11%.
  • The last Return On Invested Capital (11.24%) for AMRX is above the 3 year average (10.04%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 1.96%
ROE N/A
ROIC 11.24%
ROA(3y)-1.27%
ROA(5y)-1.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)10.04%
ROIC(5y)8.08%
AMRX Yearly ROA, ROE, ROICAMRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 -200 -300 -400

1.3 Margins

  • AMRX has a Profit Margin of 2.39%. This is amongst the best in the industry. AMRX outperforms 80.63% of its industry peers.
  • In the last couple of years the Profit Margin of AMRX has declined.
  • AMRX has a better Operating Margin (13.18%) than 85.34% of its industry peers.
  • In the last couple of years the Operating Margin of AMRX has grown nicely.
  • AMRX has a Gross Margin (36.88%) which is in line with its industry peers.
  • In the last couple of years the Gross Margin of AMRX has grown nicely.
Industry RankSector Rank
OM 13.18%
PM (TTM) 2.39%
GM 36.88%
OM growth 3Y13.53%
OM growth 5Y12.51%
PM growth 3YN/A
PM growth 5Y-12.19%
GM growth 3Y0.83%
GM growth 5Y2.08%
AMRX Yearly Profit, Operating, Gross MarginsAMRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. AMRX Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMRX is creating some value.
  • Compared to 1 year ago, AMRX has more shares outstanding
  • AMRX has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for AMRX has been reduced compared to a year ago.
AMRX Yearly Shares OutstandingAMRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M
AMRX Yearly Total Debt VS Total AssetsAMRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.2 Solvency

  • An Altman-Z score of 1.96 indicates that AMRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • The Altman-Z score of AMRX (1.96) is comparable to the rest of the industry.
  • The Debt to FCF ratio of AMRX is 11.66, which is on the high side as it means it would take AMRX, 11.66 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 11.66, AMRX is in the better half of the industry, outperforming 78.01% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 11.66
Altman-Z 1.96
ROIC/WACC1.15
WACC9.77%
AMRX Yearly LT Debt VS Equity VS FCFAMRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

  • A Current Ratio of 2.17 indicates that AMRX has no problem at all paying its short term obligations.
  • AMRX has a worse Current ratio (2.17) than 60.21% of its industry peers.
  • AMRX has a Quick Ratio of 1.48. This is a normal value and indicates that AMRX is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of AMRX (1.48) is worse than 67.54% of its industry peers.
Industry RankSector Rank
Current Ratio 2.17
Quick Ratio 1.48
AMRX Yearly Current Assets VS Current LiabilitesAMRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. AMRX Growth Analysis

3.1 Past

  • AMRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.83%, which is quite impressive.
  • The Earnings Per Share has been growing slightly by 5.92% on average over the past years.
  • The Revenue has grown by 8.05% in the past year. This is quite good.
  • The Revenue has been growing by 8.66% on average over the past years. This is quite good.
EPS 1Y (TTM)44.83%
EPS 3Y7.3%
EPS 5Y5.92%
EPS Q2Q%75%
Revenue 1Y (TTM)8.05%
Revenue growth 3Y10.92%
Revenue growth 5Y8.66%
Sales Q2Q%11.47%

3.2 Future

  • Based on estimates for the next years, AMRX will show a small growth in Earnings Per Share. The EPS will grow by 5.77% on average per year.
  • Based on estimates for the next years, AMRX will show a decrease in Revenue. The Revenue will decrease by -0.47% on average per year.
EPS Next Y20.21%
EPS Next 2Y19.5%
EPS Next 3Y18.59%
EPS Next 5Y5.77%
Revenue Next Year2.6%
Revenue Next 2Y4.84%
Revenue Next 3Y5.45%
Revenue Next 5Y-0.47%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AMRX Yearly Revenue VS EstimatesAMRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B
AMRX Yearly EPS VS EstimatesAMRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1

More info and screens

Find the best growth stocksShow best growing peers

8

4. AMRX Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 15.06 indicates a correct valuation of AMRX.
  • Based on the Price/Earnings ratio, AMRX is valued cheaply inside the industry as 86.39% of the companies are valued more expensively.
  • When comparing the Price/Earnings ratio of AMRX to the average of the S&P500 Index (27.47), we can say AMRX is valued slightly cheaper.
  • A Price/Forward Earnings ratio of 12.53 indicates a correct valuation of AMRX.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of AMRX indicates a rather cheap valuation: AMRX is cheaper than 84.29% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of AMRX to the average of the S&P500 Index (22.62), we can say AMRX is valued slightly cheaper.
Industry RankSector Rank
PE 15.06
Fwd PE 12.53
AMRX Price Earnings VS Forward Price EarningsAMRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, AMRX is valued cheaper than 86.91% of the companies in the same industry.
  • AMRX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. AMRX is cheaper than 85.34% of the companies in the same industry.
Industry RankSector Rank
P/FCF 17.88
EV/EBITDA 10.27
AMRX Per share dataAMRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of AMRX may justify a higher PE ratio.
  • AMRX's earnings are expected to grow with 18.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.74
PEG (5Y)2.54
EPS Next 2Y19.5%
EPS Next 3Y18.59%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AMRX Dividend Analysis

5.1 Amount

  • AMRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AMRX Fundamentals: All Metrics, Ratios and Statistics

AMNEAL PHARMACEUTICALS INC

NASDAQ:AMRX (4/23/2026, 8:00:01 PM)

Premarket: 12.9 +0.25 (+1.98%)

12.65

-0.17 (-1.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-27
Earnings (Next)05-01
Inst Owners45.62%
Inst Owner Change0.05%
Ins Owners43.95%
Ins Owner Change8.28%
Market Cap4.04B
Revenue(TTM)3.02B
Net Income(TTM)72.06M
Analysts81.82
Price Target16.83 (33.04%)
Short Float %4.33%
Short Ratio3.43
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.37%
Min EPS beat(2)11.53%
Max EPS beat(2)21.21%
EPS beat(4)4
Avg EPS beat(4)28.29%
Min EPS beat(4)11.53%
Max EPS beat(4)40.37%
EPS beat(8)7
Avg EPS beat(8)21.12%
EPS beat(12)11
Avg EPS beat(12)30.53%
EPS beat(16)12
Avg EPS beat(16)21.16%
Revenue beat(2)0
Avg Revenue beat(2)-0.8%
Min Revenue beat(2)-1.18%
Max Revenue beat(2)-0.41%
Revenue beat(4)0
Avg Revenue beat(4)-2.73%
Min Revenue beat(4)-4.71%
Max Revenue beat(4)-0.41%
Revenue beat(8)3
Avg Revenue beat(8)-0.24%
Revenue beat(12)6
Avg Revenue beat(12)0.1%
Revenue beat(16)8
Avg Revenue beat(16)-0.09%
PT rev (1m)13.79%
PT rev (3m)13.79%
EPS NQ rev (1m)0.92%
EPS NQ rev (3m)-15.57%
EPS NY rev (1m)3.53%
EPS NY rev (3m)6.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.71%
Revenue NY rev (1m)-1%
Revenue NY rev (3m)-3.78%
Valuation
Industry RankSector Rank
PE 15.06
Fwd PE 12.53
P/S 1.34
P/FCF 17.88
P/OCF 11.87
P/B N/A
P/tB N/A
EV/EBITDA 10.27
EPS(TTM)0.84
EY6.64%
EPS(NY)1.01
Fwd EY7.98%
FCF(TTM)0.71
FCFY5.59%
OCF(TTM)1.07
OCFY8.43%
SpS9.46
BVpS-0.22
TBVpS-3.86
PEG (NY)0.74
PEG (5Y)2.54
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA 1.96%
ROE N/A
ROCE 14.23%
ROIC 11.24%
ROICexc 12.5%
ROICexgc 23.19%
OM 13.18%
PM (TTM) 2.39%
GM 36.88%
FCFM 7.47%
ROA(3y)-1.27%
ROA(5y)-1.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)10.04%
ROIC(5y)8.08%
ROICexc(3y)10.72%
ROICexc(5y)8.59%
ROICexgc(3y)22.54%
ROICexgc(5y)18.52%
ROCE(3y)13.13%
ROCE(5y)10.51%
ROICexgc growth 3Y26.84%
ROICexgc growth 5Y18.51%
ROICexc growth 3Y34.73%
ROICexc growth 5Y26.54%
OM growth 3Y13.53%
OM growth 5Y12.51%
PM growth 3YN/A
PM growth 5Y-12.19%
GM growth 3Y0.83%
GM growth 5Y2.08%
F-Score7
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 11.66
Debt/EBITDA 4.22
Cap/Depr 51.15%
Cap/Sales 3.79%
Interest Coverage 2.01
Cash Conversion 54.71%
Profit Quality 313.13%
Current Ratio 2.17
Quick Ratio 1.48
Altman-Z 1.96
F-Score7
WACC9.77%
ROIC/WACC1.15
Cap/Depr(3y)37.69%
Cap/Depr(5y)34.67%
Cap/Sales(3y)3.12%
Cap/Sales(5y)3.19%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.83%
EPS 3Y7.3%
EPS 5Y5.92%
EPS Q2Q%75%
EPS Next Y20.21%
EPS Next 2Y19.5%
EPS Next 3Y18.59%
EPS Next 5Y5.77%
Revenue 1Y (TTM)8.05%
Revenue growth 3Y10.92%
Revenue growth 5Y8.66%
Sales Q2Q%11.47%
Revenue Next Year2.6%
Revenue Next 2Y4.84%
Revenue Next 3Y5.45%
Revenue Next 5Y-0.47%
EBIT growth 1Y14.22%
EBIT growth 3Y25.92%
EBIT growth 5Y22.25%
EBIT Next Year43.16%
EBIT Next 3Y20.98%
EBIT Next 5Y8.1%
FCF growth 1Y2.51%
FCF growth 3YN/A
FCF growth 5Y-6.32%
OCF growth 1Y15.21%
OCF growth 3Y73.5%
OCF growth 5Y-2.15%

AMNEAL PHARMACEUTICALS INC / AMRX Fundamental Analysis FAQ

What is the fundamental rating for AMRX stock?

ChartMill assigns a fundamental rating of 5 / 10 to AMRX.


What is the valuation status for AMRX stock?

ChartMill assigns a valuation rating of 8 / 10 to AMNEAL PHARMACEUTICALS INC (AMRX). This can be considered as Undervalued.


Can you provide the profitability details for AMNEAL PHARMACEUTICALS INC?

AMNEAL PHARMACEUTICALS INC (AMRX) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for AMRX stock?

The Price/Earnings (PE) ratio for AMNEAL PHARMACEUTICALS INC (AMRX) is 15.06 and the Price/Book (PB) ratio is -57.


Can you provide the expected EPS growth for AMRX stock?

The Earnings per Share (EPS) of AMNEAL PHARMACEUTICALS INC (AMRX) is expected to grow by 20.21% in the next year.